Last Update 03 Mar 26

RIGL: Future Returns Will Reflect Elevated 2026 Guidance And Lower Risk Profile

Analysts have lifted their price target on Rigel Pharmaceuticals by $2, citing updated assumptions around long term revenue growth, profit margins, discount rates, and a higher future P/E multiple.

Analyst Commentary

Bullish Takeaways

Bullish analysts point to the higher price target as a reflection of confidence in Rigel Pharmaceuticals' long term revenue potential and its ability to convert that into earnings over time.
The adjustment in valuation assumptions, including a higher future P/E multiple, suggests that some analysts see scope for improved market perception if execution on the current pipeline and commercial efforts stays on track.
Updated discount rate assumptions indicate that bullish analysts are more comfortable with the company specific risk profile, which can support a higher equity value even without relying on aggressive growth forecasts.
By explicitly revisiting profit margin assumptions, supportive analysts are signaling that they see room for more efficient operations and a clearer path to sustainable profitability, which feeds directly into their higher target.

Bearish Takeaways

Bearish analysts remain cautious that the higher price target still depends on Rigel Pharmaceuticals meeting long term revenue and margin assumptions that may be sensitive to clinical, regulatory, and competitive outcomes.
Some more cautious views focus on execution risk, highlighting that any delays in the pipeline or commercialization plans could challenge the uplift implied by the new target, even if the current P/E framework appears reasonable.
There is also concern that the use of a higher future P/E multiple may leave less room for error, so any shortfalls in growth or profitability could compress the multiple and limit upside relative to the revised target.
Cautious analysts emphasize that while the updated discount rate supports a higher valuation, it also assumes that company specific risks do not increase, which is not guaranteed in a sector exposed to clinical and regulatory setbacks.

What's in the News

Rigel Pharmaceuticals issued full year 2026 guidance, projecting total revenue of about US$275 million to US$290 million, including expected net product sales of US$255 million to US$265 million and contract revenue of US$20 million to US$25 million (Company guidance).
The company shared updated data from its ongoing Phase 1b study of R289, an oral prodrug of R835 that targets IRAK1/4, in patients with relapsed or refractory lower risk myelodysplastic syndrome, with results presented at the 67th American Society of Hematology Annual Meeting (Company announcement).
Rigel reported that 33 patients were enrolled in the Phase 1b R289 study as of October 28, 2025 and that enrollment in the dose escalation phase was completed in July 2025, with the dose expansion phase underway to help determine the recommended Phase 2 dose (Company announcement).
R289 has received Orphan Drug designation for myelodysplastic syndromes and Fast Track designation for previously treated transfusion dependent lower risk MDS from the U.S. Food and Drug Administration (Company announcement).

Valuation Changes

Fair Value: stays unchanged at $51.6, indicating no adjustment to the core valuation output.
Discount Rate: edges higher from 7.21% to 7.23%, reflecting a small increase in the required return used in the model.
Revenue Growth: moves up slightly from 7.17% to 7.42%, signaling a modest uplift in long term growth assumptions.
Net Profit Margin: shifts down from 34.32% to 28.53%, meaning the model now assumes lower long run profitability.
Future P/E: rises from 10.14x to 12.12x, pointing to a higher assumed valuation multiple on future earnings.

10 views

Key Takeaways

Expansion of the commercial portfolio, improved patient affordability, and strategic partnerships position Rigel for sustained revenue growth and enhanced market presence.
Advancing a diversified clinical pipeline with expedited regulatory pathways supports future earnings potential and aligns with the shift to targeted precision medicine.
Heavy product dependence, one-off Medicare tailwinds, pipeline risks, inflated collaboration revenue, and intensifying competition threaten Rigel's future growth, earnings stability, and market relevance.

Catalysts

About Rigel Pharmaceuticals

A biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer.What are the underlying business or industry changes driving this perspective?

The expansion and diversification of Rigel's commercial portfolio, including accelerated sales growth for TAVALISSE, GAVRETO, and REZLIDHIA, positions the company to capitalize on the rising global demand for novel therapies as the population ages-supporting robust future revenue and topline earnings growth.
Enhanced patient affordability from healthcare policy changes (notably the $2,000 Part D out-of-pocket cap) has materially improved drug accessibility and supported record new patient starts, suggesting a sustainable tailwind for Rigel's sales volumes and potential improvement in net margins by increasing commercial scale.
Rigel's advancing clinical pipeline, highlighted by progress in Phase 1b/2 studies for R289 (IRAK1/4 inhibitor in lower-risk MDS) and olutasidenib (expansion into glioma and other IDH1-mutant cancers), is aligned with the ongoing shift towards targeted, precision medicine-driving future revenue streams and expanding the company's total addressable market.
Multiple expedited regulatory designations (FDA Orphan Drug, Fast Track for R289) and streamlined pathways are likely to accelerate time-to-market for pipeline assets, enabling Rigel to realize earlier cash flows and improved long-term earnings potential if approvals are successful.
Ongoing international market expansion and strategic global partnerships leverage broader health expenditure trends and increase the potential for recurring royalties and milestone revenues, directly supporting long-term sustained revenue growth and cash flow stability.

Rigel Pharmaceuticals Earnings and Revenue Growth

Rigel Pharmaceuticals Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Rigel Pharmaceuticals's revenue will grow by 3.5% annually over the next 3 years.
Analysts assume that profit margins will shrink from 36.5% today to 14.3% in 3 years time.
Analysts expect earnings to reach $42.4 million (and earnings per share of $2.16) by about August 2028, down from $97.8 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $53.4 million in earnings, and the most bearish expecting $35.7 million.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 20.9x on those 2028 earnings, up from 5.6x today. This future PE is greater than the current PE for the US Biotechs industry at 16.9x.
Analysts expect the number of shares outstanding to grow by 1.95% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.79%, as per the Simply Wall St company report.

Rigel Pharmaceuticals Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Rigel's recent surge in revenue growth was significantly driven by improved patient affordability following the 2025 Medicare Part D out-of-pocket cap (via the Inflation Reduction Act), creating a one-time structural tailwind; as this benefit normalizes and patient "carryover" effects diminish, underlying organic growth may revert to lower long-term rates, negatively impacting future revenue expansion.
The company's commercial portfolio depends heavily on three products, with Tavalisse as the major contributor; this concentration increases vulnerability to competition, payer coverage changes, or market saturation, which could quickly affect top-line revenue, operating leverage, and earnings stability.
Pipeline expansion and future revenue growth are reliant on the success of R289 and olutasidenib in new indications; failure to demonstrate significant efficacy versus established and emerging competitors (such as luspatercept and imetelstat in MDS) or delays/setbacks in clinical development would limit pipeline diversification and long-term revenue prospects.
Current profitability includes a large noncash revenue recognition from the Lilly collaboration opt-out, inflating recent earnings and cash position; future collaboration revenue may be less predictable or substantial, and underlying operating cash flows could remain pressured by high R&D costs, impacting net margins and sustainability.
Growing competition in hematology and oncology, with more targeted therapies and biologics (e.g., cell/gene therapies), may erode demand for Rigel's small-molecule assets, and as the pace of innovation accelerates, Rigel risks losing commercial relevance, constraining long-term market share and revenue growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $38.333 for Rigel Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $67.0, and the most bearish reporting a price target of just $23.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $297.0 million, earnings will come to $42.4 million, and it would be trading on a PE ratio of 20.9x, assuming you use a discount rate of 6.8%.
Given the current share price of $30.44, the analyst price target of $38.33 is 20.6% higher. Despite analysts expecting the underlying buisness to decline, they seem to believe it's more valuable than what the market thinks.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Rigel Pharmaceuticals?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Expansion And Clinical Pipeline Will Drive Future Opportunities Despite Risks